Release of other pro-inflammatory adipokines, such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNFα) and chemerin may also contribute to metabolic disorders such as insulin resistance, dyslipidemia, hypertension and cardiovascular disease [8–10], which are associated with the development of the metabolic syndrome [11]. Here, TNF is linked to metabolic syndrome.